trending Market Intelligence /marketintelligence/en/news-insights/trending/SpJ39ptbtkey7-RNGRTDFw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J to acquire XBiotech's anti-inflammatory antibody for $750M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


J&J to acquire XBiotech's anti-inflammatory antibody for $750M

Johnson & Johnson's Janssen Biotech Inc. agreed to acquire all rights to XBiotech Inc.'s anti-inflammatory antibody bermekimab for $750 million in cash.

Austin, Texas-based XBiotech is developing bermekimab as a potential treatment for different cancer types, diabetes, cardiovascular diseases and skin disorders, including atopic dermatitis or eczema — a chronic condition that makes skin thick, dry, red and itchy — and hidradenitis suppurativa, which causes infected bumps of skin filled with pus and scarring.

In addition to the cash payment, which will be made upon deal close, XBiotech may receive up to $600 million in potential milestone payments. The company anticipates generating additional revenue from its manufacturing supply and clinical services agreements with Janssen for the next two years.

XBiotech will use the transaction's proceeds to fund the discovery and development of new true human anti-IL-1 alpha antibody program. A portion will also go to advancing the company's other antibody therapeutics.

Furthermore, the company will conduct a capital transaction, including a stock repurchase, pending board review and approval, using the proceeds.

Completion of the acquisition is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Act. The deal will close shortly after antitrust approval, XBiotech said.